SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BofA clients sold equities last week as buybacks slow

Investing.com -- Bank of America (BofA) clients turned net sellers of U.S. equities last week, pulling $1.4 billion from the market despite a 1.5% gain in the S&P 500.

Stellantis N.V. (STLA) on Tuesday affirmed the first-half results it preannounced last week and reinstated the financial guidance it had suspended in April.Reinitiating the financial guidance, the legacy automaker said it expects higher net revenue for the second half of the year. The company also guided to low-single-digit adjusted operating income (AOI) profitability and improved industrial free cash flow.&nbsp;The guidance was withdrawn in April, citing “evolving tariff policies, as well as the difficulty in predicting possible impacts on market volumes and the competitive landscape.”The Franco-Italian-American company said it now expects a 2025 net tariff impact of 1.5 billion euros ($1.73 billion), of which 0.3 billion euros was incurred in the first half.&nbsp;Stellantis added that it “remains highly engaged with relevant policymakers, while continuing long-term scenario planning.”U.S. President Donald Trump on Sunday reached a framework agreement with the European Union (EU) regarding tariffs, alleviating some headwinds.&nbsp;In Tuesday’s early premarket session, <a href="https://stocktwits.com/symbol/STLA">Stellantis stock</a> fell 3.40% to $9.38. The stock is down about 21% year-to-date.On Stocktwits, sentiment toward the stock worsened to ‘neutral’ by early Tuesday from ‘bullish’ a day ago, while the message volume continued to remain ‘high.’<figure class="image"><img style="aspect-ratio:617/51;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_29_at_4_30_49_AM_png_795ca1898e.webp" alt="Screenshot 2025-07-29 at 4.30.49 AM.png" width="617" height="51"><figcaption>STLA sentiment and message volume as of 4:30 a.m. ET, July 29 | source: Stocktwits</figcaption></figure>A watcher, citing an analyst comment, said the second-half guidance was less optimistic than expected, particularly the free cash flow.<stembedurl>https://stocktwits.com/TheNew_Mr_Investor/message/622815269</stembedurl>CEO Antonio Filosa, who took over the reins in late May, said, “2025 is turning out to be a tough year, but also one of gradual improvement.”“Our new leadership team, while realistic about the challenges, will continue making the tough decisions needed to re-establish profitable growth and significantly improved results.”The company confirmed the preliminary first-half revenue of 74.3 billion euros, marking a 13% year-over-year (YoY) decline. The company attributed this weakness primarily to declines in North America and the enlarged European regions.The automaker reversed to a loss of 2.3 billion euros, which included a 3.3 billion-euro charge, from a profit of 5.6 billion euros the previous year. Sequentially, the company saw an improvement in shipments, AOI and industrial free cash flows, benefiting from an expanded product lineup, revitalized marketing, and strong inventory discipline.Issuing an update on&nbsp;the commercial recovery plan, Stellantis said it launched four models: the Citroën C3 Aircross, Fiat Grande Punto, Opel/Vauxhall Frontera, and Ram ProMaster Cargo battery electric vehicle (BEV) in the first half.It also revamped popular products, such as the Ram 2500 and 3500 Heavy Duty, the Citroën C4/C4X, and the Opel Mokka.The new products increased the EU30 market share by 127 basis points, leading to a significant improvement in American order books.It plans to launch 10 new models in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/india-dethrones-china-as-top-smartphone-shipper-to-us-in-q2-as-amid-apple-s-supply-chain-shift/cho9nzdR5UJ">India Dethrones China As Top Smartphone Shipper To US In Q2 As Apple’s Supply‑Chain Shift Gains Traction</a>

General view of Stellantis logo on the new Hybrid and PHEV Vehicles Stellantis Group eDCT Assembly Plant on April 10, 2024, in Turin, Italy. 

Stellantis Stock Slides Premarket As Auto Giant’s Reinstated Guidance Leaves Investors Unimpressed 

Stellantis N.V. (STLA) on Tuesday affirmed the first-half results it preannounced last week and reinstated the financial guidance it had suspended in April.

Equity

CEO Antonio Filosa, who took over the reins in late May, said, “2025 is turning out to be a tough year, but also one of gradual improvement.”


Chinese e-commerce giant Alibaba Group Holding Ltd. (BABA), which has a significant tech presence, has entered the artificial intelligence (AI)-powered smart glasses market, potentially competing with Meta Platforms (META).The Jack Ma-co-founded company previewed its Quark AI glasses, named after its AI assistant, at the World Artificial Intelligence Conference (WAIC) being held in Shanghai.“Alibaba is making its entrance into the future of wearables with the debut of Quark AI Glasses — its first-ever smart eyewear powered by Qwen and Quark’s multimodal AI,” the company said in a statement released via Alizila, the English news hub of the company.The Quark AI glasses would be sleek, lightweight, and loaded with useful features such as hands-free calling, real-time translation, music streaming, and even meeting transcriptions.&nbsp;“Designed for professionals, travelers, and tech enthusiasts, the glasses seamlessly connect with Alibaba’s ecosystem — from Amap navigation to Taobao price comparisons, Alipay payments, and Fliggy travel alerts — all via voice commands,” the Hangzhou-headquartered company said.The company said the AI glasses will launch in China by the end of 2025, adding that “Quark AI Glasses is designed to fulfill Alibaba’s mission to make AI relevant, always-on, and everywhere.”In Monday's early premarket session, <a href="https://stocktwits.com/symbol/BABA">Alibaba stock</a> was up nearly 2% at $122.38.Alibaba updated its Quark personal assistant this year, and it is now available as an app in China. A CNBC report stated that the company’s foray into hardware manufacturing may have been aimed at gaining more traction for the app.The AI smart glasses market is currently dominated by Meta, which built it in collaboration with Ray-Ban. Fellow Chinese firm Xiaomi launched its version earlier this year.&nbsp;Apple (AAPL) could launch AI-powered glasses in 2027, according to Taiwan-based analyst Ming-Chi Kuo.A report from SNS Insider stated that the AI smart glasses market could be worth $3.01 billion by 2032, growing at a compound annual growth rate (CAGR) of 11% between 2025 and 2032.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/semiconductor-stocks-on-radar-as-lutnick-says-us-probe-into-chips-imports-to-drop-2-weeks/choeikdR5D0">Semiconductor Stocks On Radar As Lutnick Says US Probe Into Chip Imports Will Drop In 2 Weeks — Retail Stays Hopeful</a>

2025/07/18: The "Alibaba" logo on a blue background at the 3rd China International Supply Chain Expo. 

Alibaba’s AI Glasses Are Coming For Meta — And They’re Packed With Features

The Quark AI glasses would be sleek, lightweight, and equipped with useful features such as hands-free calling, real-time translation, music streaming, and even meeting transcription capabilities.

Tesla, Inc.’s (TSLA) underperforming stock came under further pressure in extended trading on Wednesday after a double miss, punctuated by weakness at the electric-vehicle maker’s automotive business.Tesla was among the top five trending tickers on Stocktwits late Wednesday, with retail sentiment nose-diving to ‘bearish’ territory (35/100) by late Wednesday from the ‘neutral’ mood seen a day ago.As retail traders discussed the results, the message volume increased to ‘high’ levels.<figure class="image"><img style="aspect-ratio:618/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_11_51_47_PM_png_aa1bb08cae.webp" alt="Screenshot 2025-07-23 at 11.51.47 PM.png" width="618" height="54"><figcaption>TSLA sentiment and message volume as of 11:50 p.m. ET, July 23 | source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/TSLA">Tesla stock</a>, which has lost nearly 18% year-to-date, fell 4.39% in overnight trading.&nbsp;Key numbers from the quarterly report for the second quarter of the second quarter of 2025 are as follows:<ul style="list-style-type:disc;"><li>Adjusted earnings per share (EPS): $0.40 vs. $0.52 year-ago</li><li>Revenue: $22.50&nbsp;billion vs. $25.50&nbsp;billion (down 12% YoY)</li><li>Automotive revenue: $16.66&nbsp;billion vs.$19.88&nbsp;billion (down 16% YoY)</li><li>Energy generation &amp; Storage: $2.79&nbsp;billion vs. $3.01&nbsp;billion (down 7% YoY)</li><li>Gross margin: 17.2% vs. 18%</li></ul>&nbsp;The adjusted EPS trailed the Fiscal.ai-compiled consensus of $0.41, but revenue beat the mean analysts’ estimate of $22.13 billion.The YoY revenue drop, the biggest since the third quarter of 2012,&nbsp; came about due to declines in EV deliveries and the average selling price, as well as lower regulatory credit. The company stated that these factors impacted profitability, along with higher operating expenses related to artificial intelligence (AI) and other research and development (R&amp;D) projects.On the earnings call, CFO Vaibhav Taneja flagged potential adverse&nbsp;effects for the energy business from President Donald Trump’s “one big, beautiful” bill (through expiration of energy credit) and tariffs.In a statement, Tesla said, “Q2 2025 was a seminal point in Tesla’s history: the beginning of our transition from leading the electric vehicle and renewable energy industries to also becoming a leader in AI, robotics, and related services.”The company stated that it had produced its first builds of the more affordable version in June, with volume production expected in the second half of 2025. The Tesla Semi and&nbsp;Cybercab (a two-passenger, fully autonomous EV designed for the robotaxi service) are slated for volume production in 2026.Offering an update on the robotaxi launch, CEO Elon Musk stated on the earnings call that the company would “greatly increase” the Austin service area&nbsp;beyond what&nbsp;the competition is doing in a couple of weeks, according to a Transcript made available&nbsp;by Koyfin.He also flagged the likelihood of securing regulatory permission to launch in the Bay Area, Nevada, Arizona, Florida, and&nbsp;several other locations.Comparing robotaxi service with Alphabet, Inc.’s (GOOGL) Waymo, Musk said, “Tesla is actually much better than Google by far and … anyone at real-world AI.”&nbsp;&nbsp;Alphabet CEO Sundar Pichai, meanwhile, said on the company’s earnings call that Waymo “launched in Atlanta, more than doubled its Austin service territory, and expanded its Los Angeles and San Francisco Bay Area territories by approximately 50%.”Pichai also said the company is testing across more than 10 cities this year, including New York and Philadelphia.Retail chatter around Tesla earnings was bordering on bearishness. One user braced for a “bloodbath” on Thursday.<stembedurl>https://stocktwits.com/SirBullsAlot/message/622216373</stembedurl>Pointing to Musk’s comments on the earnings call about the next few quarters being rough, a user questioned the logic behind people buying the stock.<stembedurl>https://stocktwits.com/Guntz/message/622213772</stembedurl>While answering analysts’ questions, Musk said the next few quarters, probably up to the second quarter of 2025, could be rough. “But once you get to autonomy at scale in the second half of next year, certainly by the end of next year, I think I would be surprised if Tesla's economics are not very compelling,” he added.The Koyfin-compiled consensus price target of $305.05 for the Tesla stock implies further downside (8.27%) from Wednesday’s close.For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor's note: This copy has been updated to clarify that Tesla began production of its more affordable models in June.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alphabet-ceo-sundar-pichai-hails-standout-q2-as-ai-powers-growth-across-divisions/ch8yiiLR5ua">Alphabet CEO Sundar Pichai Hails ‘Standout’ Q2 As AI Powers Growth Across Divisions — Retail Cheers Rising Google Search Momentum</a>

In this photo illustration, a Tesla logo is seen displayed on a smartphone with the image of Elon Musk in the background. 

Elon Musk Warns Of ‘Rough’ Quarters Ahead For Tesla, But ‘Affordable’ EV Hopes Cushion Stock Slide: Retail Mood Nosedives 

The YoY revenue drop, the biggest since the third quarter of 2012,  came about due to declines in EV deliveries and the average selling price, as well as lower regulatory credit.

Tesla, Inc. (TSLA) shares edged up in Wednesday’s early premarket session ahead of the electric vehicle (EV) maker’s earnings report due after the market close.Stung by a demand slowdown amid macroeconomic uncertainties, and CEO Elon Musk’s political overtures and concerns over his divided attention to his flagship business,&nbsp;<a href="https://stocktwits.com/symbol/TSLA">Tesla stock</a> is down nearly 18% for the year. This contrasts with the S&amp;P 500’s 8% advance over the same period.The stock, which is part of the Magnificent Seven group of mega-cap companies, is the&nbsp;worst-performing among them. The<a href="https://stocktwits.com/symbol/MAGS"> Roundhill Magnificent Seven ETF (MAGS)</a>, an exchange-traded fund (ETF) that tracks the performance of these seven stocks, has gained 5.46% year-to-date.According to Fiscal.ai-compiled consensus, Tesla is expected to report adjusted earnings per share (EPS) of $0.41 and revenue of $22.13 billion for the second quarter of the fiscal year 2025&nbsp;versus the year-ago quarter’s $0.40 and $25.5 billion, respectively. However, the metrics are expected to improve from the first quarter’s $0.27 and $19.34 billion, respectively.Earlier this month, Tesla reported vehicle deliveries of 384,122 units for the second quarter, down sharply from the year-ago’s 443,956 units but up from 336,681 units reported for the previous quarter.Investors are likely to look past the second-quarter numbers and focus on Tesla’s update on the robotaxi rollout.&nbsp;Questions compiled by the shareholder services platform provider Say, on behalf of Tesla investors, showed that those representing 2.9 million Tesla shares wanted information on “how robotaxis have been performing so far and what rate they are expected to expand in terms of vehicles, geofence, cities, and supervisors.”Tesla launched the service in Texas last month to mixed reviews.In a note released on Tuesday, Roth Capital stated that the positives at&nbsp;Robotaxi and Optimus are likely to outweigh the weakness in second-quarter EV sales, as reported by The Fly. The firm has assigned a ‘Buy’ rating and a $395 price target to Tesla stock.BofA Securities raised&nbsp;Tesla's stock price target to $314 from $305 this week but maintained a ‘Neutral’ rating. The firm sees a challenging second quarter due to Trump tariffs and the disappointing second-quarter deliveries.&nbsp;The focus is also likely to be on the impact of the Trump administration’s decision to eliminate the federal tax credit for EVs.&nbsp;On Stocktwits, sentiment toward Tesla stock was at ‘neutral’ (53/100) early Wednesday, with the message volume staying at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:623/51;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_5_46_59_AM_png_a96248b552.webp" alt="Screenshot 2025-07-23 at 5.46.59 AM.png" width="623" height="51"><figcaption>TSLA sentiment and message volume as of 5:40 a.m. ET, July 23 | source: Stocktwits</figcaption></figure>A bearish watcher called upon fellow retail traders to short the stock, fearing a “bad” earnings report.<stembedurl>https://stocktwits.com/BennyBoy18/message/622045171</stembedurl>However, a bullish user&nbsp;suggested that Tesla stock could move in tandem with its overseas auto peers, reacting to the Japan trade deal, and potentially rise ahead of earnings.&nbsp;<stembedurl>https://stocktwits.com/Okadarlan/message/622046056</stembedurl>The Koyfin-compiled consensus price target for Tesla stock is $305.05, implying roughly 8% downside from current levels.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/abivax-spikes-460-percent-on-positive-late-stage-ulcerative-colitis-drug-trial-results/ch8wSLiR5MQ">Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results — Retail Buzz Builds Around Blockbuster Potential</a>

A lineup of various Tesla models on display at the Edmonton Motor Show on April 13, 2025, in Edmonton, Alberta, Canada. 

Tesla Earnings Ahead: Can Robotaxi Hype Offset Q2 Auto Woes?

According to Fiscal.ai-compiled consensus, Tesla is expected to report adjusted earnings per share of $0.41 and revenue of $22.13 billion for the second quarter of the fiscal year 2025.

BofA flags broad client equity inflows as market continues to grind higher

Investing.com -- Bank of America (BofA) Securities reported broad-based equity inflows last week among its clients as the market edged higher, with the S&P 500 gaining 0.6%.

U.S. equities see largest client outflows in 10 weeks, BofA says

Investing.com -- Last week, clients were net sellers of U.S. equities for the first time in three weeks, even as the S&P 500 rallied to new record highs.

RBC upgrades Materials, cuts Discretionary in sector reshuffle

Investing.com -- RBC Capital Markets reshuffled its U.S. sector recommendations in its mid-year “Global Sector Navigator” report, upgrading Materials to Overweight while cutting Consumer Discretionary to Underweight.

Wolfe stays defensive but sees AI spending supporting growth stocks

Investing.com -- Wolfe Research maintained a defensive investment stance amid economic uncertainty, but continues to back growth stocks with exposure to artificial intelligence. 

IYC
iShares U.S. Consumer Discretionary ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IYC News

IYCiShares U.S. Consumer Discretionary ETF